MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma.

MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Abstract Text:

Shugo Tamada,Hiroaki Shibahara,Michiyo Higashi,Masamichi Goto,Surinder K Batra,Kohzoh Imai,Suguru Yonezawa,

PURPOSE: Many of the patients with extrahepatic bile duct carcinoma (EHBDC) show a poor outcome. We have reported that MUC4 is a novel prognostic factor of pancreatic adenocarcinoma and intrahepatic cholangiocarcinoma. The aim of this study is to evaluate the prognostic significance of MUC4 expression in EHBDC. EXPERIMENTAL DESIGN: We examined the expression profile of MUC4 in EHBDC tissues from 70 patients using immunohistochemistry. MUC4 is a membrane mucin like MUC1. In addition, MUC4 is an intramembrane ligand for receptor tyrosine kinase ErbB2 and is related with regulation of p27. We compared the MUC4 expression with MUC1, ErbB2, or p27 expression in EHBDC. RESULTS: MUC4 was expressed in 36 of the 70 patients with EHBDC. There was no significant correlation between the MUC4 expression and MUC1, ErbB2, or p27 expression. The survival of 19 patients with high MUC4 expression (>or=20% of carcinoma cells stained) was significantly worse than that of the 51 patients with low MUC4 expression (under 20% of carcinoma cells stained; P = 0.0072). The univariate analysis showed that high MUC4 expression (P = 0.0072), high MUC1 expression (P = 0.0092), histologic grading (P = 0.0029), surgical margin involvement (P = 0.0137), and nodal metastasis (P = 0.0036) were statistically significant risk factors. The backward stepwise multivariate analysis showed that high MUC4 expression (P = 0.0195) and surgical margin involvement (P = 0.0358) were statistically significant independent risk factors. CONCLUSIONS: MUC4 expression in EHBDC is a new independent factor for poor prognosis and predicts the outcome of patients with EHBDC.

MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Publishing Authors By Initials

S Tamada,H Shibahara,M Higashi,M Goto,SK Batra,K Imai,S Yonezawa,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Clinical cancer research : an official journal of

VOLUME: 12

Page Numbers: 4257-64

Journal Abbreviation:

ISSN: 1078-0432

DAY: 15

MONTH: Jul

YEAR: 2006

MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9502500

MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma.

AFFILIATION: Department of Human Pathology, Field of Oncology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma Related Publications

• AMP-activated Protein Kinase Phosphorylates Golgi-specific Brefeldin A Resistance Factor 1 at Thr1337 to Induce Disassembly of Golgi Apparatus.
• Altered GalNAc-alpha-2,6-sialylation compartments for mucin-associated sialyl-Tn antigen in colorectal adenoma and adenocarcinoma.
• Angiomatoid malignant fibrous histiocytoma associated with marked bleeding arising in chronic radiodermatitis.
• Characteristic distribution of cathepsin E which immunologically cross-reacts with the 86-kDa acid proteinase from rat gastric mucosa.
• Development-dependent expression of cathepsins d and e in various rat tissues, with special reference to the high expression of cathepsin e in fetal liver.
• Expression of MUC1 and MUC2 mucins and relationship with cell proliferative activity in human colorectal neoplasia.
• Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: its relationship with tumor progression and prognosis.
• Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in mucinous carcinoma of the breast: comparison with invasive ductal carcinoma.
• Flow characteristics of hepatic tumors at color Doppler sonography: correlation with arteriographic findings.
• Hypokalemia and agitation in acute psychotic patients.
• MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells.
• MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer.
• MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma.
• MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma.
• MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type.
• Mucin expression in pleomorphic adenoma of salivary gland: a potential role for MUC1 as a marker to predict recurrence.
• Mucin expression profile in pancreatic cancer and the precursor lesions.
• New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy.
• Prolonged QT interval in acute psychotic patients.
• Short-marks recording characteristics of laser-pumped magnetic-field-modulation recording in a narrow track pitch and on magnetically induced superresolution disks.
• Size-controlled oxidation-resistant copper fine particles covered by biopolymer nanoskin.
• Suppression of the mTOR-raptor signaling pathway by the inhibitor of heat shock protein 90 geldanamycin.
• Synthesis of novel trifluoromethyl-bearing bifunctional acyl-acceptant arenes: 2,2'-bis(trifluoromethylated aryloxy)biphenyls.
• The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1.
• [A new method of vital staining of the conduction system during open heart surgery--a clinical study]
• [Clinical experiences with pyrrolnitrin ointment and spray in dermatomycosis]
• [Serum beta 2 microglobulin for the early recognition of acute renal dysfunction after cardiac surgery]